Overview
Broadwood Partners, L.P., a noted shareholder in Insight Molecular Diagnostics (NASDAQ: IMDX), executed a set of open-market purchases between April 16 and April 20, 2026, acquiring a total of $652,875 worth of common stock. The stock purchases were made at prices that ranged from $3.20 to $3.99 per share. At the time of reporting, IMDX is trading at $3.99, reflecting a 33% gain over the past week while remaining down 46.8% year-to-date.
Transaction details
On April 16, 2026, Broadwood Partners purchased 102,057 shares of Insight Molecular Diagnostics common stock at a weighted average price of $3.4457 per share. The individual trade prices recorded for that day ranged from $3.20 to $3.59.
On April 17, 2026, Broadwood Partners added 40,114 shares at a weighted average price of $3.5711 per share, with per-share prices on that date spanning $3.45 to $3.84.
The most recent reported acquisition occurred on April 20, 2026, when Broadwood Partners bought 40,690 shares at a weighted average price of $3.8822 per share. The transaction prices observed that day ranged from $3.75 to $3.99.
Ownership and securities held
Following these purchases, Broadwood Partners, L.P. holds a total of 12,114,700 shares of IMDX common stock. In addition, the reporting entities hold warrants to purchase 150,093 shares of common stock at an exercise price of $30.60 per share. These warrants are currently exercisable and are scheduled to expire on April 19, 2027.
According to the filings, the direct purchases by Broadwood Partners, L.P. may be deemed beneficially owned by Broadwood Capital, Inc., the General Partner, and by Neal C. Bradsher, President of Broadwood Capital, Inc., who are also listed as reporting persons. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest. The filings also note that Neal C. Bradsher directly holds 157 shares of Insight Molecular Diagnostics common stock.
Valuation and company metrics
InvestingPro analysis referenced in the filings indicates that IMDX carries a Fair Value of $3.58 at current levels. The platform lists Insight Molecular Diagnostics with a market capitalization of $128.35 million and describes the company as operating with a moderate level of debt.
InvestingPro subscribers are noted as having access to additional insights for IMDX, including data points on cash burn and profitability outlook, as well as a comprehensive Pro Research Report covering the company as part of its broader US equities coverage.
Recent company developments
Insight Molecular Diagnostics reported fourth-quarter 2025 results that highlighted strategic progress. The company announced the submission of its GraftAssureDx assay to the U.S. Food and Drug Administration, signaling a move toward commercialization. The company also expanded its testing portfolio to include heart transplant testing.
On the equity research front, BTIG reiterated a Neutral rating on the company and noted the recent submission of a kitted transplant test to the FDA, with approval expected later this year. Needham maintained a Buy rating with a $9 price target, citing the launch of GraftAssureIQ for research use and reporting 37 sign-ups for that product in the fourth quarter, exceeding the company’s initial goal of 20 sign-ups for 2025.
Context and closing
The April purchases by Broadwood Partners are documented in the company’s filings and reflect incremental open-market accumulation at prices that span the low- to high-$3.00s per share. The filings also make clear the ownership and warrant positions tied to the reporting entities and the limited disclaimers of beneficial ownership included in those filings. The company’s regulatory submissions and product launches were highlighted in its fourth-quarter 2025 earnings disclosure and are noted in the accompanying analyst commentary.